Phase 1 trial of vorolanib plus everolimus for advanced kidney cancer
A new combination of vorolanib, a tyrosine kinase inhibitor plus [...]
ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer
A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]
ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
Generic everolimus approved by the FDA
The US Food and Drug Administration (FDA) has approved generic [...]
Panobinostat plus everolimus not effective in metastatic kidney cancer
A recent phase I clinical trial assessed the combination of [...]
SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer
We are delighted to announce that the Scottish Medicines Consortium (SMC), [...]
ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer
Results from the ENTRATA clinical trial to assess telaglenastat in [...]
PD-L1 expression and clinical outcomes with targeted therapy
A recent study published in Clinical Cancer Research analysed tumour [...]
ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib
The results from the following study were presented at the [...]
Current role of mTOR inhibitors in metastatic kidney cancer
The following video interview with Dr Eric Jonasch, from the [...]
